Viscoelastic Monitoring in Small-Animal Critical Illness

Hemostasis in the ICU is rarely simple. Viscoelastic monitoring in small-animal critical illness gives clinicians a dynamic whole-blood view of clot formation, clot strength, and clot breakdown that routine plasma-based assays often miss. For dogs and cats with sepsis, trauma, immune-mediated hemolytic anemia, neoplasia, pyometra, heatstroke, or severe inflammatory disease, that added physiologic detail can help clarify whether the dominant problem is hypercoagulability, bleeding risk, fibrinolytic dysregulation, or a shifting mix of all three.

For veterinary emergency and critical care teams, this matters because prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet count, fibrinogen, and D-dimer remain useful but incomplete. They can identify selected abnormalities, yet they do not fully describe how a patient’s whole blood behaves as a clot forms and lyses. This article reviews what viscoelastic testing adds, where the veterinary evidence is strongest, and how to apply these data without overinterpreting them.

Related reading: disseminated intravascular coagulation in dogs and cats
Related reading: thromboprophylaxis in canine IMHA
Related reading: emergency transfusion medicine protocols

Why conventional coagulation tests miss critical hemostatic phenotypes

Routine coagulation tests still belong in any hemostatic workup. PT and aPTT help identify abnormalities in plasma clotting factor pathways. Platelet count gives a numeric estimate of circulating platelets. Fibrinogen and D-dimer provide additional context. But in critically ill dogs and cats, those assays do not reliably define the patient’s net hemostatic phenotype.

That gap exists because PT and aPTT are plasma-based tests designed around time to initial fibrin formation under standardized laboratory conditions. They do not directly assess platelet-fibrin interactions, final clot strength, red cell contributions, or real-time fibrinolysis. A patient can therefore have prolonged clotting times and still be predominantly thrombosis-prone, or show normal routine results while developing marked whole-blood hypercoagulability.

This mismatch becomes especially important in inflammatory and thromboinflammatory disease. Immune-mediated hemolytic anemia, sepsis, trauma, neoplasia, and heatstroke can all alter thrombin generation, endothelial activation, platelet behavior, and fibrinolytic control at the same time. In that setting, a “normal coagulation panel” does not necessarily mean normal hemostasis.

What viscoelastic monitoring measures in dogs and cats

Thromboelastography (TEG) and thromboelastometry (ROTEM/TEM) measure the viscoelastic properties of whole blood as a clot forms and later breaks down. Platform terminology varies, but the physiologic concepts are similar.

Clot initiation, propagation, and clot strength

Early parameters such as reaction time or clotting time reflect the onset of fibrin generation. Intermediate parameters such as clot formation time and alpha angle describe how quickly the clot propagates. Later measurements such as maximum amplitude or maximum clot firmness estimate final clot strength, which is influenced heavily by platelet contribution and fibrinogen function.

This whole-blood perspective is the key advantage. Instead of stopping at the first appearance of fibrin, viscoelastic testing follows the clot through its major functional phases. That makes it especially useful when the clinical question is not simply “Are coagulation factors deficient?” but rather “Is this patient forming a stable clot, an excessively strong clot, or a fragile clot that is breaking down too fast?”

Fibrinolysis and fibrinolytic shutdown

One of the most clinically useful features of viscoelastic monitoring is its ability to evaluate fibrinolysis. Routine coagulation tests give only indirect clues to clot breakdown. Viscoelastic tracings can instead suggest whether a clot is undergoing excessive lysis, minimal lysis, or a shutdown pattern that may favor persistent clot burden.

That matters because both ends of the spectrum can be dangerous. Hyperfibrinolysis can contribute to hemorrhage even if initial clot formation appears acceptable. Fibrinolytic shutdown may support ongoing thrombosis risk and organ dysfunction. Veterinary review literature suggests these abnormalities are likely underrecognized in small-animal critical care, especially when clinicians rely on conventional assays alone.

Still, viscoelastic testing is not a perfect proxy for in vivo hemostasis. Results are influenced by platform, activator choice, sample handling, temperature, platelet count, hematocrit, and local reference intervals. For that reason, it works best as an adjunctive test rather than a standalone answer.

Disease states where viscoelastic monitoring is most useful

The current veterinary literature supports selective use of viscoelastic monitoring in diseases where thrombosis, bleeding, or fibrinolytic dysregulation are plausible and where routine tests may not explain the bedside picture.

Immune-mediated hemolytic anemia

Canine immune-mediated hemolytic anemia (IMHA) remains one of the clearest veterinary examples of clinically important hypercoagulability. Thromboembolic complications, particularly pulmonary thromboembolism, contribute substantially to morbidity and mortality. Consensus guidance from the CURATIVE group and multiple reviews support thromboprophylaxis as a core part of management in many patients at risk.

Viscoelastic data in IMHA consistently support a hypercoagulable phenotype in many dogs. That does not mean every dog with IMHA should be managed by viscoelastic tracing alone. It does mean PT, aPTT, and platelet count can underestimate the degree to which clot strength and thrombosis risk dominate the case. In practice, viscoelastic monitoring can help define whether the patient’s hemostatic profile aligns with the disease’s recognized prothrombotic biology.

Sepsis, parvoviral enteritis, and systemic inflammation

Sepsis-associated hemostatic dysfunction is biologically complex. Endothelial injury, platelet activation, inflammatory cytokines, thrombin generation, and altered fibrinolysis may all occur simultaneously. Human critical care literature has framed this as thromboinflammation, and that lens is increasingly relevant in veterinary patients as well.

Direct sepsis-specific veterinary viscoelastic studies remain limited, but related inflammatory diseases offer strong clues. Dogs with parvoviral enteritis have shown a range of viscoelastic abnormalities from hypo- to hypercoagulability, along with evidence suggesting reduced fibrinolytic activity. In pyometra, combined standard coagulation testing and thromboelastography has supported excessive coagulation activation, delayed fibrinolysis, and a non-overt DIC phenotype in some patients.

The practical point is straightforward: inflammatory ICU patients do not all clot the same way. Viscoelastic monitoring may reveal phenotypic heterogeneity long before that heterogeneity becomes obvious from PT and aPTT alone.

Trauma, hemorrhage, and transfusion decision-making

Trauma is one of the most mature applications of viscoelastic testing in human medicine. The major translational lesson is not that veterinary patients mirror humans perfectly, but that trauma-related coagulopathy is dynamic. A patient can move from bleeding risk and hypocoagulability toward later hypercoagulability, with major changes in fibrinolysis along the way.

For small-animal critical care, viscoelastic testing may be especially helpful in three trauma-related scenarios:

• distinguishing delayed clot formation from poor clot strength
• identifying a possible hyperfibrinolytic phenotype in ongoing hemorrhage
• informing more individualized transfusion and hemostatic support decisions

The evidence base is still thinner than in human trauma care, but the physiologic rationale is strong. When the question is whether a bleeding patient lacks clot strength, is consuming factors, or is lysing clot too quickly, whole-blood dynamic testing is often more clinically intuitive than plasma clotting times alone.

Neoplasia, pyometra, and heatstroke

Neoplasia is a recognized thrombotic risk factor in dogs, although the magnitude and phenotype vary by tumor type and clinical context. Pazzi and colleagues prospectively showed a substantial prevalence of thromboemboli and microthrombi in dogs with carcinoma or sarcoma, linking laboratory hemostatic disturbances to clinically relevant thrombosis.

In pyometra, recent work has suggested a hypercoagulable state with delayed fibrinolysis, consistent with non-overt DIC dominated more by excessive coagulation activation than immediate consumptive bleeding. In heatstroke, thromboelastometry has identified hypocoagulable phenotypes associated with worse outcome, DIC, and acute kidney injury, while also showing that coagulation profiles may shift over time.

These disease models reinforce the same principle: viscoelastic monitoring is most useful when clinicians expect a changing, phenotype-dependent coagulation disturbance rather than a single static defect.

How to interpret hypercoagulable, hypocoagulable, and mixed tracings

A major strength of viscoelastic monitoring is that it moves clinicians away from an oversimplified “normal versus abnormal” view of coagulation. In critical care, the more useful question is often, “What hemostatic phenotype best describes this patient right now?”

Broadly, clinicians interpret tracings in the following way:

1. Hypercoagulable pattern: shortened initiation or propagation phases and increased clot strength. This may support thrombosis risk, especially in IMHA, neoplasia, inflammatory disease, and selected endocrine or protein-losing disorders.
2. Hypocoagulable pattern: delayed initiation, impaired clot propagation, and reduced clot strength. This may fit severe hemorrhage, advanced shock, consumptive coagulopathy, hepatic dysfunction, or late-stage systemic disease.
3. Fibrinolytic abnormality: either excessive clot breakdown or minimal lysis consistent with shutdown. Both patterns can be clinically relevant.
4. Mixed or shifting phenotype: many ICU patients do not stay in one category. Repeated testing may show movement from early bleeding risk toward later thrombotic risk, or vice versa.

That said, interpretation should remain disciplined. A hypercoagulable tracing alone does not mandate antithrombotic treatment, and a hypocoagulable tracing alone does not prove that clinical bleeding is caused by systemic coagulopathy. Clinical context remains essential. Platelet count, fibrinogen, hematocrit, D-dimer, disease mechanism, imaging, hemorrhage pattern, and serial change all matter.

Clinical limitations and evidence gaps

The case for viscoelastic monitoring is strong, but the evidence is not complete. Several limitations still constrain how confidently clinicians can act on these data.

First, veterinary studies are often small, observational, and disease-specific. Second, assay protocols differ between centers, including activators, machines, sample handling, and reference intervals. Third, there is no fully standardized veterinary definition of hypercoagulability, hypocoagulability, or clinically important fibrinolysis across all platforms.

Most importantly, there remains a major gap between physiologic detection and outcome validation. It is one thing to show that a patient is hypercoagulable on TEG or ROTEM. It is another to prove that a viscoelastic-guided intervention improves survival, reduces thrombosis, or decreases clinically important bleeding in dogs and cats.

This uncertainty should not be hidden. It should be stated plainly. The present evidence supports viscoelastic monitoring as a valuable adjunct for hemostatic phenotyping and individualized interpretation. It does not yet support treating it as a universally outcome-proven algorithm for every ICU patient.

Practical takeaways for veterinary emergency and critical care teams

For most clinicians, the best current use of viscoelastic monitoring in small-animal critical illness is selective rather than routine. It is most helpful when the clinical picture and standard testing do not line up cleanly, when clot strength or fibrinolysis are central questions, or when disease biology strongly suggests thrombosis risk despite ambiguous routine results.

In practice, viscoelastic monitoring is most likely to add value when:

• the patient appears thrombosis-prone despite prolonged or only mildly abnormal PT/aPTT
• transfusion or hemostatic support decisions need a more functional whole-blood assessment
• hyperfibrinolysis or fibrinolytic shutdown is suspected
• serial monitoring may clarify a changing coagulation phenotype over time

The bottom line is that viscoelastic monitoring in small-animal critical illness fills an important gap between conventional coagulation assays and bedside reality. It is not a replacement for PT, aPTT, platelet count, fibrinogen, or sound clinical judgment. But in the right patient, it offers a more complete view of clot behavior and a better framework for understanding whether bleeding risk, hypercoagulability, or fibrinolytic dysregulation is driving the case.

As veterinary emergency and critical care continues to move toward phenotype-based medicine, viscoelastic testing will likely become more important. The next step is not wider enthusiasm alone. It is better standardization, stronger prospective studies, and outcome-based trials that show when acting on these tracings changes what matters most for patients.

Frequently Asked Questions

What does viscoelastic monitoring show that PT and aPTT do not?

Viscoelastic monitoring evaluates whole-blood clot formation over time, including clot propagation, clot strength, and fibrinolysis. PT and aPTT mainly assess the time to initial fibrin formation in plasma, so they miss important information about platelet-fibrin interaction and clot breakdown.

When should viscoelastic testing be used in small-animal critical illness?

It is most useful when routine coagulation tests do not match the clinical picture, when thrombosis risk is suspected despite ambiguous standard results, or when clinicians need better assessment of clot strength or fibrinolysis in bleeding or inflammatory ICU patients.

Is a hypercoagulable viscoelastic tracing enough to start anticoagulation?

No. A hypercoagulable tracing should be interpreted alongside disease context, platelet count, fibrinogen, imaging findings, and overall thrombotic risk. It can support decision-making, but it should not be treated as a standalone mandate for anticoagulant therapy.

Which veterinary diseases most commonly show useful viscoelastic abnormalities?

The strongest veterinary evidence exists for immune-mediated hemolytic anemia, inflammatory critical illness, parvoviral enteritis, pyometra, heatstroke, trauma-related coagulopathy, and neoplasia-associated thrombosis risk. These conditions often show patterns not fully captured by conventional coagulation testing.